Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?

Reducing the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) is the key ultimate goal set in essentially all treatment guidelines. There has been solid evidence supporting the relationship between serum hepatitis B virus (HBV) DNA level and risk of HCC. Antivir...

Descripción completa

Detalles Bibliográficos
Autores principales: Yip, Terry Cheuk-Fung, Lai, Jimmy Che-To, Wong, Grace Lai-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567686/
https://www.ncbi.nlm.nih.gov/pubmed/32974760
http://dx.doi.org/10.1007/s00535-020-01726-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567686/
https://www.ncbi.nlm.nih.gov/pubmed/32974760
http://dx.doi.org/10.1007/s00535-020-01726-3

Ejemplares similares